Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (19) 19
humans (16) 16
aspirin (15) 15
stroke (14) 14
aged (13) 13
female (13) 13
male (13) 13
cardiac & cardiovascular systems (11) 11
risk factors (11) 11
atrial fibrillation (10) 10
stroke - prevention & control (9) 9
warfarin (9) 9
myocardial infarction (8) 8
rivaroxaban (8) 8
treatment outcome (8) 8
apixaban (7) 7
bleeding (7) 7
middle aged (7) 7
anticoagulants (6) 6
aspirin - adverse effects (6) 6
atrial fibrillation - drug therapy (6) 6
care and treatment (6) 6
clinical trials (6) 6
management (6) 6
therapy (6) 6
abridged index medicus (5) 5
aspirin - therapeutic use (5) 5
atrial fibrillation - complications (5) 5
cardiac patients (5) 5
cardiovascular diseases (5) 5
double-blind method (5) 5
hemorrhage (5) 5
hemorrhage - chemically induced (5) 5
kaplan-meier estimate (5) 5
metaanalysis (5) 5
mortality (5) 5
peripheral vascular disease (5) 5
pyrazoles - adverse effects (5) 5
pyridones - adverse effects (5) 5
stroke - etiology (5) 5
thrombosis (5) 5
anticoagulation (4) 4
atherosclerosis (4) 4
brain ischemia - prevention & control (4) 4
cardiovascular disease (4) 4
drug therapy (4) 4
embolism (4) 4
fibrinolytic agents - adverse effects (4) 4
fibrinolytic agents - therapeutic use (4) 4
heart failure (4) 4
prevention (4) 4
pyrazoles - therapeutic use (4) 4
pyridones - therapeutic use (4) 4
thrombectomy (4) 4
vitamin k (4) 4
aged, 80 and over (3) 3
aspirin - administration & dosage (3) 3
atrial-fibrillation (3) 3
cardiovascular diseases - mortality (3) 3
cerebral infarction (3) 3
clinical neurology (3) 3
clopidogrel (3) 3
coronary vessels (3) 3
death (3) 3
factor xa inhibitors - adverse effects (3) 3
fibrillation (3) 3
fibrinolytic agents - administration & dosage (3) 3
follow-up studies (3) 3
guidelines (3) 3
heart attack (3) 3
heart attacks (3) 3
life sciences (3) 3
medical research (3) 3
myocardial infarction - therapy (3) 3
optical coherence tomography (3) 3
oral anticoagulants (3) 3
patient outcomes (3) 3
percutaneous coronary intervention (3) 3
prevent stroke (3) 3
proportional hazards models (3) 3
prospective studies (3) 3
randomized controlled trial (3) 3
risk assessment (3) 3
risk stratification (3) 3
risk-factors (3) 3
safety (3) 3
stroke prevention (3) 3
thromboembolism (3) 3
thromboembolism - prevention & control (3) 3
time factors (3) 3
age (2) 2
age factors (2) 2
analysis (2) 2
anticoagulants - administration & dosage (2) 2
anticoagulants - adverse effects (2) 2
article (2) 2
association (2) 2
atrial fibrillation - diagnosis (2) 2
atrial fibrillation - mortality (2) 2
blood clots (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial
by Diener, Hans-Christoph, Prof, Dr and Eikelboom, John, Prof and Connolly, Stuart J, Prof and Joyner, Campbell D, Prof and Hart, Robert G, Prof and Lip, Gregory YH, Prof and O'Donnell, Martin, MD and Hohnloser, Stefan H, Prof and Hankey, Graeme J, Prof and Shestakovska, Olga, MSc and Yusuf, Salim, Prof and AVERROES Steering Comm Investigato and AVERROES Steering Committee and Investigators
Lancet Neurology, The, ISSN 1474-4422, 2012, Volume 11, Issue 3, pp. 225 - 231
Summary Background In the AVERROES study, apixaban, a novel factor Xa inhibitor, reduced the risk of stroke or systemic embolism in patients with atrial... 
Neurology | MANAGEMENT | PREVENT STROKE | TASK-FORCE | WARFARIN | CLINICAL NEUROLOGY | Pyrazoles - therapeutic use | Ischemic Attack, Transient - drug therapy | Atrial Fibrillation - drug therapy | Humans | Middle Aged | Male | Treatment Outcome | Stroke - drug therapy | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Female | Aged | Aspirin - therapeutic use | Pyridones - therapeutic use | Stroke (Disease) | Care and treatment | Aspirin | Ischemia | Atrial fibrillation | Abnormalities | Clinical trials | Muscle contraction | Stroke | Fibrillation | Transient ischemic attack | Regression analysis | Age | Bleeding | Embolism | Risk factors | Vitamin K | Kardiologi | Medical and Health Sciences | Cardiology | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy
by Jolly, Sanjit S and Cairns, John A and Yusuf, Salim and Meeks, Brandi and Pogue, Janice and Rokoss, Michael J and Kedev, Sasko and Thabane, Lehana and Stankovic, Goran and Moreno, Raul and Gershlick, Anthony and Chowdhary, Saqib and Lavi, Shahar and Niemelä, Kari and Steg, Philippe Gabriel and Bernat, Ivo and Xu, Yawei and Cantor, Warren J and Overgaard, Christopher B and Naber, Christoph K and Cheema, Asim N and Welsh, Robert C and Bertrand, Olivier F and Avezum, Alvaro and Bhindi, Ravinay and Pancholy, Samir and Rao, Sunil V and Natarajan, Madhu K and ten Berg, Jurriën M and Shestakovska, Olga and Gao, Peggy and Widimsky, Petr and Džavík, Vladimír and TOTAL Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 15, pp. 1389 - 1398
Patients with STEMI were assigned to primary PCI with or without thrombectomy. At 180 days, there was no significant between-group difference in the primary... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | METAANALYSIS | ANGIOPLASTY | MANAGEMENT | THROMBUS ASPIRATION | GUIDELINES | PERFUSION | OUTCOMES | ST-SEGMENT ELEVATION | ELEVATION MYOCARDIAL-INFARCTION | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Thrombectomy - adverse effects | Combined Modality Therapy - adverse effects | Coronary Thrombosis - therapy | Myocardial Infarction - complications | Myocardial Infarction - therapy | Stroke - etiology | Coronary Thrombosis - complications | Cardiovascular Diseases - mortality | Electrocardiography | Microvessels | Female | Aged | Heart Failure - etiology | Percutaneous Coronary Intervention - adverse effects | Care and treatment | Usage | Patient outcomes | Cardiac patients | Surgery | Health aspects | Heart attack | Risk factors | Embolism | Myocardial infarction | Cerebral infarction | Medical research | Heart attacks | Heart surgery | Clinical trials | Thrombosis | Blood clots | Perfusion | Coronary vessels | Implants | Embolization | Death | Microvasculature | Cardiovascular diseases | Heart diseases | Heart failure | Stroke | Funding | Mortality | Catheters | Bailouts
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
by Eikelboom, John W and Connolly, Stuart J and Bosch, Jackie and Dagenais, Gilles R and Hart, Robert G and Shestakovska, Olga and Diaz, Rafael and Alings, Marco and Lonn, Eva M and Anand, Sonia S and Widimsky, Petr and Hori, Masatsugu and Avezum, Alvaro and Piegas, Leopoldo S and Branch, Kelley R.H and Probstfield, Jeffrey and Bhatt, Deepak L and Zhu, Jun and Liang, Yan and Maggioni, Aldo P and Lopez-Jaramillo, Patricio and O’Donnell, Martin and Kakkar, Ajay K and Fox, Keith A.A and Parkhomenko, Alexander N and Ertl, Georg and Störk, Stefan and Keltai, Matyas and Ryden, Lars and Pogosova, Nana and Dans, Antonio L and Lanas, Fernando and Commerford, Patrick J and Torp-Pedersen, Christian and Guzik, Tomek J and Verhamme, Peter B and Vinereanu, Dragos and Kim, Jae-Hyung and Tonkin, Andrew M and Lewis, Basil S and Felix, Camilo and Yusoff, Khalid and Steg, P. Gabriel and Metsarinne, Kaj P and Cook Bruns, Nancy and Misselwitz, Frank and Chen, Edmond and Leong, Darryl and Yusuf, Salim and COMPASS Investigators
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events... 
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights